These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 11166518

  • 41. Drug-induced growth hormone and prolactin responses in schizophrenia research.
    Lal S, Nair NP, Iskandar HI, Thavundayil JX, Etienne P, Wood PL, Guyda H.
    Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):631-7. PubMed ID: 6131495
    [Abstract] [Full Text] [Related]

  • 42. Dopamine agonists at repeated "autoreceptor-selective" doses: effects upon the sensitivity of A10 dopamine autoreceptors.
    Jeziorski M, White FJ.
    Synapse; 1989; 4(4):267-80. PubMed ID: 2603146
    [Abstract] [Full Text] [Related]

  • 43. Psychopathological correlates of dopaminergic disturbances in major depression.
    Pitchot W, Hansenne M, Moreno AG, von Frenckell R, Ansseau M.
    Neuropsychobiology; 1989; 24(4):169-72. PubMed ID: 2135707
    [Abstract] [Full Text] [Related]

  • 44. Effects of spiperone, raclopride, SCH 23390 and clozapine on apomorphine inhibition of sensorimotor gating of the startle response in the rat.
    Swerdlow NR, Keith VA, Braff DL, Geyer MA.
    J Pharmacol Exp Ther; 1991 Feb; 256(2):530-6. PubMed ID: 1825226
    [Abstract] [Full Text] [Related]

  • 45. Predictors of response to clozapine.
    Lieberman JA, Kane JM, Safferman AZ, Pollack S, Howard A, Szymanski S, Masiar SJ, Kronig MH, Cooper T, Novacenko H.
    J Clin Psychiatry; 1994 Sep; 55 Suppl B():126-8. PubMed ID: 7961556
    [Abstract] [Full Text] [Related]

  • 46. Heterogeneity of serotonergic response in treatment-refractory schizophrenia patients.
    Lindenmayer JP, Adityanjee, Vital-Herne M, Bark N, Grochowski S, Moynihan N.
    Biol Psychiatry; 1997 Jul 01; 42(1):6-12. PubMed ID: 9193736
    [Abstract] [Full Text] [Related]

  • 47. Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses.
    Levy MI, Davis BM, Mohs RC, Kendler KS, Mathé AA, Trigos G, Horvath TB, Davis KL.
    Arch Gen Psychiatry; 1984 May 01; 41(5):520-4. PubMed ID: 6372737
    [Abstract] [Full Text] [Related]

  • 48. CCK-8 antagonizes apomorphine-induced growth hormone secretion in normal subjects.
    Nair NP, Lal S, Eugenio H, Lizondo E, Thavundayil JX, Wood PL, Etienne P, Guyda H.
    Horm Metab Res; 1986 Jan 01; 18(1):53-5. PubMed ID: 3949282
    [Abstract] [Full Text] [Related]

  • 49. 5-HT(1A) receptor dysfunction in female patients with schizophrenia.
    Lee MA, Meltzer HY.
    Biol Psychiatry; 2001 Nov 15; 50(10):758-66. PubMed ID: 11720694
    [Abstract] [Full Text] [Related]

  • 50. Effect of domperidone on apomorphine-induced growth hormone secretion in normal men.
    Lal S, Nair NP, Iskandar HL, Etienne P, Wood PL, Schwartz G, Guyda H.
    J Neural Transm; 1982 Nov 15; 54(1-2):75-84. PubMed ID: 7108512
    [Abstract] [Full Text] [Related]

  • 51. Increased growth hormone response to apomorphine in Parkinson disease compared with multiple system atrophy.
    Friess E, Kuempfel T, Winkelmann J, Schmid D, Uhr M, Rupprecht R, Holsboer F, Trenkwalder C.
    Arch Neurol; 2001 Feb 15; 58(2):241-6. PubMed ID: 11176962
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Relation of clinical symptoms to apomorphine-stimulated growth hormone release in mood-incongruent psychotic patients.
    Zemlan FP, Hirschowitz J, Garver DL.
    Arch Gen Psychiatry; 1986 Dec 15; 43(12):1162-7. PubMed ID: 3778112
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Suppression of prolactin by dopamine agonists in schizophrenics and controls.
    Rotrosen J, Angrist B, Clark C, Gershon S, Halpers FS, Sachar EJ.
    Am J Psychiatry; 1978 Aug 15; 135(8):949-51. PubMed ID: 665840
    [Abstract] [Full Text] [Related]

  • 57. Postsynaptic supersensitivity in schizophrenia.
    Pandey GN, Garver DL, Tamminga C, Ericksen S, Ali SI, Davis JM.
    Am J Psychiatry; 1977 May 15; 134(5):518-22. PubMed ID: 848578
    [Abstract] [Full Text] [Related]

  • 58. Growth hormone responses to apomorphine HCl in schizophrenic patients on drug holidays and at relapse.
    Cleghorn JM, Brown GM, Brown PJ, Kaplan RD, Dermer SW, MacCrimmon DJ, Mitton J.
    Br J Psychiatry; 1983 May 15; 142():482-8. PubMed ID: 6135481
    [Abstract] [Full Text] [Related]

  • 59. Relationship of psychotic symptom clusters in schizophrenia to neuroleptic treatment and growth hormone response to apomorphine.
    Zemlan FP, Hirschowitz J, Sautter F, Garver DL.
    Psychiatry Res; 1986 Jul 15; 18(3):239-55. PubMed ID: 2875478
    [Abstract] [Full Text] [Related]

  • 60. Evaluating prolactin response to dopamine agonists in schizophrenia. Methodological problems.
    Davis BM, Davis KL, Mohs RC, Mathé AA, Rothpearl AB, Johns CA, Levy MI, Horvath TB.
    Arch Gen Psychiatry; 1985 Mar 15; 42(3):259-64. PubMed ID: 3977547
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.